NF2 Gene Neurofibromatosis type 2 Genetic Test
Test Details
Neurofibromatosis type 2 (NF2) is a genetic disorder characterized by the development of tumors in the nervous system. It is caused by mutations in the NF2 gene, which is responsible for producing a protein called merlin. The NF2 gene acts as a tumor suppressor, helping to regulate cell growth and division.
Test Name
NF2 Gene Neurofibromatosis type 2 Genetic Test
Components
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test type: Osteology Dermatology Immunology Disorders
Doctor
Dermatologist
Test Department
Genetics
Pre Test Information
Clinical History of Patient who is going for NF2 Gene Neurofibromatosis type 2 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with NF2 Gene Neurofibromatosis type 2 NGS Genetic DNA Test gene NF2.
Test Procedure
The NF2 gene NGS genetic test involves obtaining a DNA sample, typically through a blood sample, from the individual being tested. The DNA is then sequenced using NGS technology, and the resulting sequence data is compared to a reference sequence to identify any variations or mutations in the NF2 gene.
Test Results
The results of the NF2 gene NGS genetic test can help confirm a diagnosis of NF2 in individuals with clinical symptoms suggestive of the disorder. It can also be used for genetic counseling and family planning purposes, as individuals with NF2 have a 50% chance of passing the mutated gene to their children.
It is important to note that while the NF2 gene NGS genetic test can provide valuable information, it is not a diagnostic tool on its own. A clinical evaluation by a healthcare professional, along with other diagnostic tests, may be necessary to confirm a diagnosis of NF2.
Test Name | NF2 Gene Neurofibromatosis type 2 Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Osteology Dermatology Immunology Disorders |
Doctor | Dermatologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for NF2 Gene Neurofibromatosis type 2 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with NF2 Gene Neurofibromatosis type 2 NGS Genetic DNA Test gene NF2 |
Test Details |
Neurofibromatosis type 2 (NF2) is a genetic disorder characterized by the development of tumors in the nervous system. It is caused by mutations in the NF2 gene, which is responsible for producing a protein called merlin. The NF2 gene acts as a tumor suppressor, helping to regulate cell growth and division. NGS (Next-Generation Sequencing) is a high-throughput DNA sequencing technology that allows for the rapid and accurate sequencing of large amounts of genetic material. In the context of NF2, NGS can be used to analyze the entire coding region of the NF2 gene, as well as other relevant genes, to identify any mutations or genetic variants that may be associated with the disorder. The NF2 gene NGS genetic test involves obtaining a DNA sample, typically through a blood sample, from the individual being tested. The DNA is then sequenced using NGS technology, and the resulting sequence data is compared to a reference sequence to identify any variations or mutations in the NF2 gene. The results of the NF2 gene NGS genetic test can help confirm a diagnosis of NF2 in individuals with clinical symptoms suggestive of the disorder. It can also be used for genetic counseling and family planning purposes, as individuals with NF2 have a 50% chance of passing the mutated gene to their children. It is important to note that while the NF2 gene NGS genetic test can provide valuable information, it is not a diagnostic tool on its own. A clinical evaluation by a healthcare professional, along with other diagnostic tests, may be necessary to confirm a diagnosis of NF2. |